JP2003012516A5 - - Google Patents

Download PDF

Info

Publication number
JP2003012516A5
JP2003012516A5 JP2001391481A JP2001391481A JP2003012516A5 JP 2003012516 A5 JP2003012516 A5 JP 2003012516A5 JP 2001391481 A JP2001391481 A JP 2001391481A JP 2001391481 A JP2001391481 A JP 2001391481A JP 2003012516 A5 JP2003012516 A5 JP 2003012516A5
Authority
JP
Japan
Prior art keywords
calmodulin
calcium
kinase inhibitor
dependent kinase
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001391481A
Other languages
Japanese (ja)
Other versions
JP2003012516A (en
JP4153693B2 (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2001391481A priority Critical patent/JP4153693B2/en
Priority claimed from JP2001391481A external-priority patent/JP4153693B2/en
Publication of JP2003012516A publication Critical patent/JP2003012516A/en
Publication of JP2003012516A5 publication Critical patent/JP2003012516A5/ja
Application granted granted Critical
Publication of JP4153693B2 publication Critical patent/JP4153693B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Claims (6)

式(I):
Figure 2003012516
[式中、R1、およびR2は、独立して、水素原子、ハロゲン原子、アルキル基、またはハロアルキル基のいずれかである。R3は水素原子、アルキル基、または置換アルキル基を表し、COOR3基はナフタレン環のどの位置に置換していてもよい。]で表される、7H−ベンズイミダゾ[2,1a]ベンズ[de]イソキノリン−7−オン誘導体、またはその薬学上許容される塩を有効成分として含有するカルシウム/カルモジュリン依存性キナーゼキナーゼ阻害剤。
Formula (I):
Figure 2003012516
[Wherein, R 1 and R 2 are each independently a hydrogen atom, a halogen atom, an alkyl group, or a haloalkyl group. R 3 represents a hydrogen atom, an alkyl group, or a substituted alkyl group, and the COOR 3 group may be substituted at any position on the naphthalene ring. Represented by], 7H-Benzuimida zone [1 - [alpha] benz [de] isoquinolin-7-one derivative or calcium / calmodulin-dependent kinase kinase inhibitor containing a pharmaceutically acceptable salt thereof as an active ingredient.
1およびR2が水素原子である、請求項1記載のカルシウム/カルモジュリン依存性キナーゼキナーゼ阻害剤。The calcium / calmodulin-dependent kinase kinase inhibitor according to claim 1, wherein R 1 and R 2 are hydrogen atoms. 3が水素原子である、請求項1または2記載のカルシウム/カルモジュリン依存性キナーゼキナーゼ阻害剤。The calcium / calmodulin-dependent kinase kinase inhibitor according to claim 1 or 2, wherein R 3 is a hydrogen atom. 式(II):
Figure 2003012516
[式中、R1、R2、およびR3は、式(I)と同義である。]で表される7H−ベンズイミダゾ[2,1a]ベンズ[de]イソキノリン−7−オン誘導体、またはその薬学上許容される塩を、有効成分として含有するカルシウム/カルモジュリン依存性キナーゼキナーゼ阻害剤。
Formula (II):
Figure 2003012516
[Wherein, R 1 , R 2 , and R 3 have the same meaning as in formula (I). 7H- Benzuimida zone [1 - [alpha] benz [de] isoquinolin-7-one derivative or calcium / calmodulin-dependent kinase kinase inhibitor and a pharmaceutically acceptable salt thereof, as an active ingredient, represented by.
1およびR2が水素原子である、請求項記載のカルシウム/カルモジュリン依存性キナーゼキナーゼ阻害剤。The calcium / calmodulin-dependent kinase kinase inhibitor according to claim 4 , wherein R 1 and R 2 are hydrogen atoms. 3が水素原子である、請求項4または5記載のカルシウム/カルモジュリン依存性キナーゼキナーゼ阻害剤。The calcium / calmodulin-dependent kinase kinase inhibitor according to claim 4 or 5 , wherein R 3 is a hydrogen atom.
JP2001391481A 2001-04-25 2001-12-25 Novel CaMKK inhibitor Expired - Fee Related JP4153693B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001391481A JP4153693B2 (en) 2001-04-25 2001-12-25 Novel CaMKK inhibitor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001127524 2001-04-25
JP2001-127524 2001-04-25
JP2001391481A JP4153693B2 (en) 2001-04-25 2001-12-25 Novel CaMKK inhibitor

Publications (3)

Publication Number Publication Date
JP2003012516A JP2003012516A (en) 2003-01-15
JP2003012516A5 true JP2003012516A5 (en) 2005-07-14
JP4153693B2 JP4153693B2 (en) 2008-09-24

Family

ID=26614177

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001391481A Expired - Fee Related JP4153693B2 (en) 2001-04-25 2001-12-25 Novel CaMKK inhibitor

Country Status (1)

Country Link
JP (1) JP4153693B2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207185B2 (en) 2006-10-12 2012-06-26 Duke University CaMKKβ as a target for treating obesity
US20130253035A1 (en) 2010-08-16 2013-09-26 Duke University Camkk-beta as a target for treating cancer
US9790423B2 (en) * 2013-08-05 2017-10-17 Basf Se Cyanated naphthalenebenzimidazole compounds
SG11202101522WA (en) * 2018-08-20 2021-03-30 Univ Duke Methods and compositions for drugs to treat ophthalmic diseases

Similar Documents

Publication Publication Date Title
HUP0302693A2 (en) Phenylalanin-derivatives, integrin inhibitors of alpha4, their use and process for their preparation
JP2004516314A5 (en)
CA2379560A1 (en) Purine derivatives inhibitors of tyrosine protein kinase syk
JP2010501478A5 (en)
GEP20074033B (en) Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
HUP0104666A2 (en) Thyroid receptor ligands
EP1797878A3 (en) Benzothiazole derivatives
BR0311541A (en) indole, azaindole and 4-akenyl piperidine related heterocyclic amides
PL367618A1 (en) 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht 7 serotonin receptors
JP2002525323A5 (en)
JP2003503449A5 (en)
WO2001064645A3 (en) Derivatives of quinoline as alpha-2 antagonists
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
HUP0100865A2 (en) Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists, pharmaceutical compositions comprising thereof and their use
NO20040881L (en) Oral antidiabetic agents.
RU2002100058A (en) 1-Methylcarbapenem Crystal Derivatives
JP2000159790A5 (en)
PT992509E (en) NEW MACROLIDED DERIVATIVES
JP2002506864A5 (en)
RS20060239A (en) Arylalkylcarbamate derivatives, preparation method thereof and use of same in therapeutics
JP2003012516A5 (en)
CA2300289A1 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
ZA200704584B (en) New 3-Phenylpropionic acid derivatives for the treatment of diabetes
JP2008519001A5 (en)
CA2088702A1 (en) Aminobenzoic acid derivatives